Pioglitazone (30 mg/day for 14 days)	baseline	serum IL-8 levels at day-14	24504	24658	Pioglitazone increased serum IL-8 levels at day-14 when compared to baseline day-0 values (mean change = −166.8 IU/ml; 95% CI: −300.1 to −33.5; P = 0.019)
Prednisone (40 mg/day for 4 days)	baseline	serum ALT, AST, IL-8 or other inflammatory mediators	-1	-1	Prednisone treatment did not affect at day-4 either serum ALT, AST, IL-8 or other inflammatory mediators ( Tables 9 and 10 ).
Pioglitazone (30 mg/day for 14 days)	baseline	day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF	-1	-1	We found no statistically significant differences between day-0 and day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF ( Table 6 ).
Pioglitazone (30 mg/day for 14 days)	baseline	serum IL-8 levels at day-14	-1	-1	ioglitazone increased serum IL-8 levels at day-14 when compared to baseline day-0 values (mean change?=??166.8 IU/ml; 95% CI: ?300.1 to ?33.5; P?=?0.019)
Pioglitazone (30 mg/day for 14 days)	baseline	day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF	25913	26065	We found no statistically significant differences between day-0 and day-14 in serum IL-28B, TNF-α, IL-1α, IL-1β, IL-6, IL-8, IL-10, IFN-γ, MCP-1 and HGF
Pioglitazone (30 mg/day for 14 days)	baseline	day-14 fasting serum glucose and the 2-hr glucose (Glucose-120 min) after an OGTT 	22163	22386	Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean change = 8.2 mg/dL; P = 0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean change = 18.8 mg/dL; P = 0.001) ( <NEWLINE>Table 4 <NEWLINE>)
Pioglitazone (30 mg/day for 14 days)	baseline	day-14 fasting serum glucose and the 2-hr glucose (Glucose-120 min) after an OGTT 	-1	-1	Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean change?=?8.2 mg/dL; P?=?0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean change?=?18.8 mg/dL; P?=?0.001) ( Table 4 ).
Pioglitazone (30 mg/day for 14 days)	baseline	HCV RNA at day-14	-1	-1	Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n?=?10; difference of means?=?205,618 IU/ml; 95% CI 26,600 to 384,600; P<0.001).
